In the News

Read the latest about us

Modus Therapeutics strengthens Board with two key appointments

STOCKHOLM, SWEDEN – 29 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announcesthe appointment of two new Board members. Stig Løkke Pedersen, an experienced life science industry veteran with more than 30 years’ experience, has been appointed Chairman […]

Modus Therapeutics completes enrollment of randomized, placebo-controlled Phase II clinical trial evaluating sevuparin for management of Acute Vaso-Occlusive Crisis in SCD patients

STOCKHOLM, SWEDEN – 07 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has completed patient enrollment in its Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Sevuparin Infusion for […]

Modus CEO Ellen K Donnelly interviewed for BioStock publication

Modus Therapeutics CEO Ellen K Donnelly was recently interviewed for industry publication BioStock. She joined Modus in April 2017 from Pfizer as Head of Clinical Operations, and has previously worked at Leerink Partners. Read the full interview with Ellen here